Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Vupanorsen; Drug: Placebo

• Registration Number: NCT04459767
• Lead Sponsor: Pfizer

Brief Summary

This is a Phase 1, randomized, double blind, third party open (i.e., participant blind, investigator blind and sponsor open), placebo controlled, single ascending dose study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamics of vupanorsen in Japanese healthy adult participants with elevated triglycerides.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-01
• Study First Submitted QC: 2020-07-01
• Study First Posted: 2020-07-07
• Study Start: 2020-08-06
• Status Verified: 2020-12
• Primary Completion: 2020-12-15
• Study Completion: 2020-12-15
• Last Update Submitted: 2020-12-18
• Last Update Posted: 2020-12-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Male and female participants must be 20 to 65 years of age, inclusive, at the time of signing the ICD.
2. Participants must have four Japanese grandparents born in Japan.
3. Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests (except for TG levels), and 12 lead ECG monitoring.
4. Fasting TG >= 90 mg/dL at Screening
5. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
6. BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb)
7. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Read More

Exclusion Criteria

1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.

2. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, or HCVAb.

3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

4. History of allergic or anaphylactic reaction.

5. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.

6. Previous administration with an investigational drug within 4 months or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).

7. A positive urine drug test.

8. Screening supine BP >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.

9. Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.

10. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • AST or ALT level >=1.25 × ULN;
    • Total bilirubin level >=1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is=<ULN.

11. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.

12. Blood donation (excluding plasma donations and platelet donations) of approximately 400 mL within 3 months or >=200 mL within a month prior to dosing. Additionally, approximately >=400 mL within 4 months for female participants.

13. History of sensitivity to heparin or heparin induced thrombocytopenia.

14. History of substance abuse within 12 months of the screening visit.

15. Pregnant females; breastfeeding females.

16. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.

17. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Vupanorsen 80 milligram (mg)	Vupanorsen	Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
Vupanorsen 160 mg	Vupanorsen	Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
Placebo	Placebo	Participants in Cohort 1 (vupanorsen 80 mg) will receive one 0.8 mL subcutaneous injection with 0.9% sodium chloride in water. Participants in Cohort 2 (vupanorsen 160 mg) will receive two 0.8 mL subcutaneous injections with 0.9% sodium chloride in water.

Primary Outcome Measures

Name	Time	Method
Incidence of treatment related adverse events	Day 0-90
Incidence and magnitude of abnormal laboratory findings	Day 0-90
Incidence of abnormal and clinically relevant changes in pulse rate	Day 0-90
Incidence of abnormal and clinically relevant changes in electrocardiogram	Day 0-90
Incidence of abnormal and clinically relevant changes in supine blood pressure	Day 0-90

Secondary Outcome Measures

Name	Time	Method
Area under the plasma concentration-time profile from time zero to infinity (AUCinf)	Day 0-90
Percentage changes from baseline in non-high-density lipoprotein cholesterol	Day 0-90
Percentage changes from baseline in apolipoprotein B total	Day 0-90
Apparent volume of distribution (Vz/F)	Day 0-90
Percentage changes from baseline in total cholesterol	Day 0-90
Percentage changes from baseline in triglyceride	Day 0-90
Area under the plasma concentration-time profile from time zero to 24 hours post-dose (AUC24h)	Day 0-90
Apparent clearance (CL/F)	Day 0-90
Percentage changes from baseline in serum angiopoietin-like protein 3	Day 0-90
Percentage changes from baseline in apolipoprotein A-1	Day 0-90
Maximum observed plasma concentration (Cmax)	Day 0-90
Area under the plasma concentration-time profile from time zero to the last measurable concentration (AUClast)	Day 0-90
Percentage changes from baseline in low density lipoprotein cholesterol	Day 0-90
Percentage changes from baseline in very low density lipoprotein cholesterol	Day 0-90
Percentage changes from baseline in apolipoprotein C-III	Day 0-90
Time to reach maximum observed plasma concentration (Tmax)	Day 0-90
Area under the plasma concentration-time profile from time zero to 48 hours post-dose (AUC48h)	Day 0-90
Terminal elimination half life (t1/2)	Day 0-90

Trial Locations

Locations (1)

P-one Clinic; 🇯🇵 Hachioji-shi, Tokyo, Japan